id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2014-D-0622-0021,FDA,FDA-2014-D-0622,Best Practices in Developing Proprietary Names for Human Prescription Drug Products; Guidance for Industry,Other,Guidance,2020-12-09T05:00:00Z,2020,12,2020-12-09T05:00:00Z,,2024-11-06T23:42:55Z,,1,0,090000648498e3cc
FDA-2014-D-0622-0020,FDA,FDA-2014-D-0622,Best Practices in Developing Proprietary Names for Human Prescription Drug Products; Guidance for Industry; Availability,Notice,Notice of Availability,2020-12-09T05:00:00Z,2020,12,2020-12-09T05:00:00Z,,2020-12-09T13:40:47Z,2020-27058,0,0,090000648498fb58